Henry Schein (NASDAQ:HSIC) Price Target Raised to $78.00

Henry Schein (NASDAQ:HSIC) had its price target lifted by JPMorgan Chase & Co. from $76.00 to $78.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other analysts have also commented on HSIC. Stifel Nicolaus reissued a “hold” rating and set a $75.00 price objective (down from $80.00) on shares of Henry Schein in a report on Friday, July 25th. Barrington Research set a $79.00 target price on Henry Schein and gave the company an “outperform” rating in a research report on Wednesday. Wall Street Zen lowered Henry Schein from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Robert W. Baird reaffirmed a “neutral” rating and set a $72.00 price objective (down from $82.00) on shares of Henry Schein in a report on Monday, July 14th. Finally, Evercore ISI upped their target price on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Henry Schein currently has an average rating of “Hold” and an average target price of $76.08.

Henry Schein Stock Performance

Shares of HSIC stock opened at $71.90 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51. The firm has a fifty day simple moving average of $66.30 and a two-hundred day simple moving average of $68.71. Henry Schein has a 12 month low of $60.56 and a 12 month high of $82.49. The firm has a market capitalization of $8.72 billion, a PE ratio of 23.19, a price-to-earnings-growth ratio of 2.06 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The firm had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Analysts forecast that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HSIC. Ameriprise Financial Inc. raised its position in shares of Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares during the period. Norges Bank purchased a new position in Henry Schein in the 2nd quarter valued at approximately $89,476,000. M.D. Sass LLC bought a new stake in Henry Schein during the 2nd quarter valued at $79,201,000. Schroder Investment Management Group lifted its position in shares of Henry Schein by 149.3% during the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after acquiring an additional 936,471 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after acquiring an additional 668,182 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.